While multi-biomarker approaches are certainly going to become more common (key quote: “We really are moving away from this one drug, one biomarker, one companion diagnostic,” Dr Richard Pazdur, FDA’s oncology chief), this article identifies one key challenge, and that is sample scarcity. Multi-biomarker really does need to be true multiplexing, especially for diseases where sample volume availability is limited.

The next generation of gene tests for cancer takes an all-in-one approach to tumor biomarkers (MedCity News)